BJH - volume 8, issue Abstract Book BHS, february 2017
G. Froyen PhD, J. Willemse PhD, A. Broekmans , R. Smets , B. Cruys , N. Put MD, PhD, V. Madoe , M. Janssen , O. Soepenberg , G. Bries MD, PhD, B. Maes MD, PhD
BJH - volume 7, issue Abstract Book BHS, january 2016
N. Put MD, PhD, B. Maes MD, PhD, R. Achten , K. Deraedt , K. Theunissen , V. Madoe
BJH - volume 5, issue 1, march 2014
N. Put MD, PhD, L. Michaux MD, PhD, P. Vandenberghe MD, PhD
The presence, number and/or type of chromosomal aberrations represent an independent predictor of prognosis in several haematological disorders. Therefore, (cyto)genetic analysis is now routinely performed in many haematological malignancies. Different techniques are available to detect chromosomal abnormalities. Conventional cytogenetic analysis can be performed, and also interphase fluorescent in situ hybridisation is widely used. In addition, multiplex ligation-dependent probe amplification and more recently analysis by means of different array-platforms have been used in research and routine setting. Newly developed techniques, such as next-generation sequencing are only available for research purposes thus far. All these techniques are complementary, and each technique has its own (dis)advantages.
(BELG J HEMATOL 2014;5(1):3–11)
Read moreBJH - volume 5, issue 1, march 2014
N. Put MD, PhD, L. Michaux MD, PhD, P. Vandenberghe MD, PhD
Chronic mature B-cell lymphoproliferative disorders, i.e. B-cell chronic lymphocytic leukaemia and plasma cell dyscrasias such as multiple myeloma, have a variable disease course. Clinical staging systems and several biological parameters have been used to estimate tumour burden and predict prognosis. In addition, cytogenetic aberrations have prognostic significance and are therefore investigated in the routine evaluation of these diseases. In this doctoral study, we evaluated available techniques, which can be applied to detect cytogenetic abnormalities in the routine investigation of chronic lymphocytic leukaemia and multiple myeloma. Next, we characterised cytogenetic entities, in particular translocations involving immunoglobulin genes and the proto-oncogenes BCL2 and MYC and investigated clonal evolution in chronic lymphocytic leukaemia.
(BELG J HEMATOL 2014;5(1):25–30)
Read more
Top
